Materials science tetrahedron - A useful tool for pharmaceutical research and development

Journal of Pharmaceutical Sciences

Volumn 98, Issue 5, 2009, Pages 1671-1687

  Sun, Changquan Calvin ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Formulation; Materials science; Materials science tetrahedron; Pharmaceutical manufacturing; Powder technology; Process development; Structure property relationship

Indexed keywords

PARACETAMOL; SULFAMERAZINE;

CRYSTAL STRUCTURE; DRUG FORMULATION; DRUG INDUSTRY; DRUG SOLUBILITY; MEDICAL RESEARCH; PHARMACEUTICAL ENGINEERING; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 65949115076     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21552     Document Type: Review

References (105)

1. Craig DQM. 1997. Pharmaceutical materials science - Resuscitation or reincarnation? J Pharm Pharmacol 49:119-126.
2. Cui Y. 2007. A material science perspective of pharmaceutical solids. Int J Pharm 339:3-18.
3. Shah P. 2006. Use of nanotechnologies for drug delivery. MRS Bull 31:894-899.
4. Wassgren C, Curtis JS. 2006. The application of computational modeling to pharmaceutical materials science. MRS Bull 31:900-904.
5. Temperley HNV, Blythe GEK. 1968. Mills which grind to micron size without moving parts. Nature 219:1218-1222.
6. Merisko-Liversidge E, Liversidge GG, Cooper ER. 2003. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18:113-120.
7. Zuegner S, Marquardt K, Zimmermann I. 2006. Influence of nanomechanical crystal properties on the comminution process of particulate solids in spiral jet mills. Eur J Pharm Biopharm 62:194-201.
8. Kamahara T, Takasuga M, Tung HH, Hanaki K, Fukunaka T, Izzo B, Nakada J, Yabuki Y, Kato Y. 2007. Generation of fine pharmaceutical particles via controlled secondary nucleation under high shear environment during crystallization - Process development and scale-up. Org Process Res Dev 11:699-703.
9. Matteucci ME, Hotze MA, Johnston KP, Williams RO. 2006. Drug nanoparticles by antisolvent precipitation: Mixing energy versus surfactant stabilization. Langmuir 22:8951-8959.
10. Barot M, Modi DM, Parikh JR. 2006. Novel particle engineering technology: A review. Drug Deliv Technol 6:54, 56, 58-60.
11. Kawashima Y, Okumura M, Takenaka H. 1982. Spherical crystallization: Direct spherical agglomeration of salicylic acid crystals during crystallization. Science 216:1127-1128.
12. Kawashima Y, Imai M, Takeuchi H, Yamamoto H, Kamiya K, Hino T. 2003. Improved flowability and compactibility of spherically agglomerated crystals of ascorbic acid for direct tableting designed by spherical crystallization process. Powder Technol 130:283-289.
13. Katta J, Rasmuson AC. 2008. Spherical crystallization of benzoic acid. Int J Pharm 348:61-69.
14. Chow K, Tong HHY, Lum S, Chow AHL. 2008. Engineering of pharmaceutical materials: An industrial perspective. J Pharm Sci 97:2855-2877.
15. Parikh DM, editor. 2005. Handbook of Pharmaceutical Granulation Technology, 2nd edition. Boca Raton, FL: Taylor & Francis Group.
16. Leuenberger H, Lanz M. 2005. Pharmaceutical powder technology - From art to science: The challenge of the FDA's Process Analytical Technology initiative. Adv Powder Technol 16:3-25.
17. Gordon RE, Rosanske TW, Fonner DE, Anderson NR, Banker GS. 1989. Granulation technology and tablet characterization. In: Lieberman HA, Lachman L, Schwartz JB, editors. Pharmaceutical dosage forms: Tablets Vol. 2, 2nd edition. New York: Dekker. pp 245-339.
18. FDA report. 2004. "Final Report on Pharmaceutical cGMPs for the 21st Century - A Risk-Based Approach." September 2003. http://www.fda.gov/cder/ gmp/gmp2004/GMP-finalreport2004.htm.
19. FDA Report. 2007. Critical path opportunities for generic drugs, http://www.fda.gov/oc/initiatives/criticalpath/reports/generic.html.
20. FDA White Paper. 2005. Question-based review (QbR) for generic drugs: An enhanced pharmaceutical quality assessment system, http://www.fda.gov/cder/ogd/ QbR-white-paper.htm.
21. Hussain AS. 2005. Process analytical technology: A first step in a journey towards the desired state. J Process Anal Technol 2:8-13.
22. National Research Council (US). 1999. Materials science and engineering: Forging stronger links to users, 1st edition. Washington, D.C.: National Academy Press.
23. Howell PR. 2005. Earth, air, fire & water: Elements of materials science, 2nd edition. Boston, MA: Pearson Custom Publishing.
24. FDA. 2004. PAT - A framework for innovative pharmaceutical development, manufacturing and quality assurance In Guidance for industry. http://www.fda.gov/cder/guidance/6419fnl.pdf.
25. Yu LX, Lionberger RA, Raw AS, D'Costa R, Wu H, Hussain AS. 2004. Applications of process analytical technology to crystallization processes. Adv Drug Deliv Rev 56:349-369.
26. York P. 1992. Crystal engineering and particle design for the powder compaction process. Drug Dev Ind Pharm 18:677-721.
27. Rohrs BR, Amidon GE, Meury RH, Secreast PJ, King HM, Skoug CJ. 2006. Particle size limits to meet USP content uniformity criteria for tablets and capsules. J Pharm Sci 95:1049-1059.
28. Narayan P, Hancock BC. 2003. The relationship between the particle properties, mechanical behavior, and surface roughness of some pharmaceutical excipient compacts. Mater Sci Eng A355:24-36.
29. Amidon GE, Houghton ME. 1995. The effect of moisture on the mechanical and powder flow properties of microcrystalline cellulose. Pharm Res 12:923-929.
30. Sun CC. 2008. Mechanism of moisture induced variations in true density and compaction properties of microcrystalline cellulose. Int J Pharm 346:93-101.
31. Sun CC. 2005. True density of microcrystalline cellulose. J Pharm Sci 94:2132-2334.
32. Hancock BC, Carlson GT, Ladipo DD, Langdon BA, Mullarney MP. 2001. The powder flow and compact mechanical properties of two recently developed matrix-forming polymers. J Pharm Pharmacol 53:1193-1199.
33. Sun CC, Hou H, Gao P, Ma C, Medina C, Alvarez F. 2008. Development of a high drug load tablet formulation based on assessment of powder manufacturability - Moving towards quality by design. J Pharm Sci DOI: 10.1002/jps.21422.
34. Taylor LJ, Papadopoulos DG, Dunn PJ, Bentham AC, Dawson NJ, Mitchell JC, Snowden MJ. 2004. Predictive milling of pharmaceutical materials using nanoindentation of single crystals. Org Process Res Dev 8:674-679.
35. Sun CC. 2008. On the mechanism of reduced tablet-ability of granules prepared by roller compaction. Int J Pharm 347:171-172.
36. Sun CC, Himmelspach MW. 2006. Reduced tablet-ability of roller compacted granules as a result of granule size enlargement. J Pharm Sci 95:200-206.
37. Wu SJ, Sun CC. 2007. Insensitivity of compaction properties of brittle granules to size enlargement by roller compaction. J Pharm Sci 96:1445-1450.
38. He X, Secreast PJ, Amidon GE. 2007. Mechanistic study of the effect of roller compaction and lubricant on tablet mechanical strength. J Pharm Sci 96:1342-1355.
39. Callister WD. 2000. Materials science and engineering: An introduction, 5th edition. New York: Wiley. pp 397-399.
40. Sheth AR, Grant DJW. 2005. Relationship between the structure and properties of pharmaceutical crystals. KONA 23:36-48.
41. Datta S, Grant DJW. 2004. Crystal structures of drugs: Advances in determination, prediction and engineering. Nat Rev Drug Discov 3:42-57.
42. Reddy CM, Padmanabhan KA, Desiraju GR. 2006. Structure-property correlations in bending and brittle organic crystals. Crystal Growth Des 6:2720-2731.
43. Chen X, Li T, Morris KR, Byrn SR. 2002. Crystal packing and chemical reactivity of two polymorphs of flufenamic acid with ammonia. Mol Cryst Liq Cryst Sci Technol A Mol Cryst Liq Cryst 381:121-131.
44. Reddy CM, Basavoju S, Desiraju GR. 2005. Sorting of polymorphs based on mechanical properties. Trimorphs of 6-chloro-2,4-dinitroaniline. Chem Commun 19:2439-2441.
45. Joiris E, Di Martine P, Berneron C, Guyot-Hermann AM, Guyot JC. 1998. Compression behavior of orthorhombic paracetamol. Pharm Res 15:1122-1130.
46. Pikal MJ, Rigsbee DR. 1997. The stability of insulin in crystalline and amorphous solids: Observation of greater stability for the amorphous form. Pharm Res 14:1379-1387.
47. Sukenik CN, Bonapace JAP, Mandel NS, Bergman RG, Lau P-Y, Wood G. 1975. Enhancement of a chemical reaction rate by proper orientation of reacting molecules in the solid state. J Am Chem Soc 97:5290-5291.
48. Bates S, Zografi G, Engers D, Morris KR, Crowley K, Newman A. 2006. Analysis of amorphous nanocrystalline solids from their X-ray diffraction patterns. Pharm Res 23:2333-2349.
49. Hiestand EN. 1985. Dispersion forces and plastic deformation in tablet bond. J Pharm Sci 74:768-770.
50. Hiestand EN. 1991. Tablet bond. I. A theoretical model. Int J Pharm 67:217-229.
51. Garekani HA, Ford JL, Rubinstein MH, Rajabi-Siahboomi AR. 2001. Effect of compression force, compression speed, and particle size on the compression properties of paracetamol. Drug Dev Ind Pharm 27:935-942.
52. Rees JE, Rue PJ. 1978. Time-dependent deformation of some direct compression excipients. J Pharm Pharmacol 30:601-607.
53. Roberts RJ, Rowe RC. 1986. The effect of the relationship between punch velocity and particle size on the compaction behavior of materials with varying deformation mechanisms. J Pharm Pharmacol 38:567-571.
54. Hiestand EN. 1997. Mechanical properties of compacts and particles that control tableting success. J Pharm Sci 86:985-990.
55. Hiestand EN, Smith DP. 1984. Indices of tableting performance. Powder Technol 38:145-159.
56. Sun CC, Grant DJW. 2000. Compaction properties of L-lysine salts. Pharm Res 18:281-286.
57. Sun CC, Grant DJW. 2001. Influence of crystal structure on the tableting properties of sulfamerazine polymorphs. Pharm Res 18:274-280.
58. Sun CC, Grant DJW. 2001. Influence of crystal shape on the tableting performance of L-lysine monohydrochloride dihydrate. J Pharm Sci 90:567-577.
59. Tye CK, Sun CC, Amidon GE. 2005. Evaluation of the effects of tableting speed on the relationships between compaction pressure, tablet tensile strength, and tablet solid fraction. J Pharm Sci 94:465-472.
60. Sun CC. 2006. A material-sparing method for simultaneous determination of true density and powder compaction properties - Aspartame as an example. Int J Pharm 326:94-99.
61. Otsuka M, Hasegawa H, Matsuda Y. 1997. Effect of polymorphic transformation during the extrusion-granulation process on the pharmaceutical properties of carbamazepine granules. Chem Pharm Bull 45:894-898.
62. Summers MP, Enever RP, Carless JE. 1977. Influence of crystal form on tensile strength of compacts of pharmaceutical materials. J Pharm Sci 66: 1172-1175.
63. Summers MP, Enever RP, Carless JE. 1976. The influence of crystal form on the radial stress transmission characteristics of pharmaceutical materials. J Pharm Pharmacol 28:89-99.
64. Burger A. 1982. Thermodynamic and other aspects of the polymorphism of drugs. Pharm Int 3:158-163.
65. Ibrahim HG, Pisano F, Bruno A. 1977. Polymorphism of phenylbutazone: Properties and compressional behavior of crystals. J Pharm Sci 66:669-673.
66. Burger A, Henck J-O, Hetz S, Rollinger JM, Weissnicht AA, Stöttner H. 2000. Energy/temperature diagram and compression behavior of the polymorphs of D-mannitol. J Pharm Sci 89:457-468.
67. Sun CC, Grant DJW. 2004. Improved tableting properties of p-hydroxybenzoic acid by water of crystallization: A molecular insight. Pharm Res 21:382-386. (Pubitemid 38221986)
68. Sun CC, Hou H. 2008. Improving mechanical properties of caffeine and methyl gallate crystals by cocrystallization. Crystal Growth Des 8:1575-1579.
69. Feng Y, Sun CC, Grant DJW. 2007. Influence of crystal structure on the tableting properties of n-alkyl 4-hydroxybenzoate esters (Parabens). J Pharm Sci 96:3324-3333.
70. Cooper J, Rees JE. 1972. Tableting research and technology. J Pharm Sci 61:1511-1555.
71. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
72. Pikal MJ, Lukes AL, Lang JE, CGaines K. 1978. Quantitative determination for b-lactam antibiotics by solution calorimetry: Correlation with stability. J Pharm Sci 67:767-772.
73. Saleki-Gerhardt A, Ahlneck C, Zografi G. 1994. Assessment of disorder in crystalline solids. Int J Pharm 101:237-247.
74. Berggren J, Alderborn G. 2001. Drying behaviour of two sets of microcrystalline cellulose pellets. Int J Pharm 219:113-126.
75. Berggren J, Alderborn G. 2001. Effect of drying rate on porosity and tableting behaviour of cellulose pellets. Int J Pharm 227:81-96.
76. Simon O, Guigon P. 2003. Correlation between powder-packing properties and roll press compact heterogeneity. Powder Technol 130:257-264.
77. Johansson B, Wikberg M, Ek R, Alderborn G. 1995. Compression behaviour and compactability of microcrystalline cellulose pellets in relationship to their pore structure and mechanical properties. Int J Pharm 117:57-73.
78. Badawy SIF, Gray DB, Hussain MA. 2006. A study on the effect of wet granulation on microcrystalline cellulose particle structure and performance. Pharm Res 23:634-640.
79. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 48:27-42.
80. Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. 2002. Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci 91:1863-1872.
81. Swallen SF, Kearns KL, Mapes MK, Kim YS, McMahon RJ, Ediger MD, Wu T, Yu L, Satija S. 2007. Organic glasses with exceptional thermodynamic and kinetic stability. Science 315:353-356.
82. Wu T, Yu L. 2006. Surface crystallization of indomethacin below glass transition temperature. Pharm Res 23:2350-2355.
83. Wu T, Sun Y, Li N, De Villiers MM, Yu L. 2007. Inhibiting surface crystallization of amorphous indomethacin by nanocoating. Langmuir 23:5148-5153.
84. Sun Y, Xi H, Ediger MD, Yu L. 2008. Diffusionless crystal growth from glass has precursor in equilibrium liquid. J Phys Chem B 112:661-664.
85. Brittain HG, Grant DJW. 1999. Effects of polymorphism and solid-state solvation on solubility and dissolution rate. In: Brittain HG, editor. Polymorphism in pharmaceutical solids, 1st edition. New York: Marcel Dekker, Inc. pp 279-330.
86. Sun CC. 2006. Solid-state properties and crystallization behavior of PHA-739521 polymorphs. Int J Pharm 319:114-120.
87. Wu L-S, Gerard C, Koval C, Rowe S, Hussain MA. 1994. Crystallinity, hygroscopicity and dissolution of moricizine hydrochloride hemihydrate. J Pharm Biomed Anal 12:1043-1046.
88. Shah B, Kakumanu VK, Bansal AK. 2006. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci 95:1641-1665.
89. Yamaoka T, Nakamachi H, Miyata K. 1982. Studies on the characteristics of carbochromen hydrochloride crystals. II. Polymorphism and cracking in the tablets. Chem Pharm Bull 30:3695-3700.
90. Dong Z, Padden BE, Salsbury JS, Munson EJ, Schroeder SA, Prakash I, Grant DJW. 2002. Neotame anhydrate polymorphs I: Preparation and characterization. Pharm Res 19:330-336.
91. Coury JR, Aguizr ML. 1995. Rupture of dry agglomerates. Powder Technol 85:37-43.
92. Wikberg M, Alderborn G. 1991. Compression characteristics of granulated materials. IV. The effect of granule porosity on the fragmentation propensity and the compactibility of some granulations. Int J Pharm 69:239-253.
93. Hou H, Sun CC. 2008. Quantifying effects of particulate properties on powder flow properties using a ring shear tester. J Pharm Sci 97:4030-4039.
94. Leuenberger H, Rohera BD, Haas C. 1987. Percolation theory - A novel approach to solid dosage form design. Int J Pharm 38:109-115.
95. Holman LE, Leuenberger H. 1988. The relationship between solid fraction and mechanical properties of compacts - The percolation theory model approach. Int J Pharm 46:35-44.
96. Krausbauer E, Puchkov M, Betz G, Leuenberger H. 2008. Rational estimation of the optimum amount of non-fibrous disintegrant applying percolation theory for binary fast disintegrating formulation. J Pharm Sci 97:529-541.
97. Busignies V, Leclerc B, Porion P, Evesque P, Couarraze G, Tchoreloff P. 2007. Application of percolation model to the tensile strength and the reduced modulus of elasticity of three compacted pharmaceutical excipients. Eur J Pharm Biopharm 67:507-514.
98. Kimura GP, Maxim, Betz G, Leuenberger H. 2007. Percolation theory and the role of maize starch as a disintegrant for a low water-soluble drug. Pharm Dev Technol 12:11-19.
99. Miranda A, Millan M, Caraballo I. 2007. Investigation of the influence of particle size on the excipient percolation thresholds of HPMC hydrophilic matrix tablets. J Pharm Sci 96:2746-2756.
100. Busignies V, Leclerc B, Porion P, Evesque P, Couarraze G, Tchoreloff P. 2006. Investigation and modelling approach of the mechanical properties of compacts made with binary mixtures of pharmaceutical excipients. Eur J Pharm Biopharm 64:51-65.
101. Leuenberger H. 2006. Pharmaceutical technology: Drug delivery, formulation, and process research. Chimia 60:40-45.
102. Miranda A, Millan M, Caraballo I. 2006. Study of the critical points of HPMC hydrophilic matrices for controlled drug delivery. Int J Pharm 311:75-81.
103. Amin MCI, Fell JT. 2004. Comparison studies on the percolation thresholds of binary mixture tablets containing excipients of plastic/brittle and plastic/plastic deformation properties. Drug Dev Ind Pharm 30:937-945.
104. Leuenberger H, Ineichen L. 1997. Percolation theory and physics of compression. Eur J Pharm Biopharm 44:269-272.
105. AAPS web page. http://www.aapspharmaceutica.com/inside/sections/ realignment.asp.